Rare Cell Detection via Biomarker Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnostics, particularly for early detection of metastasis, face challenges due to their invasive nature, high costs, and non-specificity, leading to over-diagnosis and unnecessary treatments.
Innovation Solution
A method for detecting rare cells in a blood sample involves enriching nucleated cells, applying a non-destructive treatment to release biomarkers, and measuring specific biomarkers using qPCR to predict the presence of rare cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If surgical biopsies are used for cancer detection, then diagnostic precision is improved, but patient discomfort and invasiveness increase
Solution Approach 1:
The patent extracts and detects specific biomarkers (miRNA, protein markers) from blood samples to identify cancer presence, replacing the need for invasive surgical biopsies. This extraction approach allows diagnosis through liquid biopsy, significantly reducing patient discomfort while maintaining diagnostic accuracy.
Solution Approach 2:
The patent replaces mechanical surgical biopsy procedures with molecular detection methods using qPCR and immunoassays to detect cancer-specific biomarkers in blood. This substitution eliminates the need for physical tissue sampling while providing equivalent or superior diagnostic information.
2Measurement precision
If non-specific protein markers like PSA are used for cancer screening, then detection sensitivity is improved, but diagnostic specificity deteriorates leading to over-diagnosis
Solution Approach 1:
The patent detects specific miRNA markers (miR-200c, miR-200b, miR-141) that are locally and specifically expressed in cancer cells, rather than using general protein markers. This localized molecular fingerprinting provides cancer-specific detection without the false positives associated with non-specific proteins like PSA.
Solution Approach 2:
The patent uses a composite approach by detecting multiple biomarkers simultaneously (panel of miRNAs plus protein markers like CEA, CA19-9) to achieve both high sensitivity and high specificity. The combination of markers compensates for individual limitations and provides comprehensive cancer detection.
3Reliability
If surgical biopsies are performed to reduce over-diagnosis, then diagnostic reliability is improved, but device complexity and operator overhead increase
Solution Approach 1:
The patent employs automated qPCR systems and robotic liquid handling to perform biomarker detection with minimal human intervention. The system self-calibrates and processes samples automatically, reducing operator overhead and simplifying the diagnostic workflow compared to manual biopsy procedures.
4Measurement precision
If invasive diagnostic procedures are used, then measurement precision is improved, but patient compliance deteriorates
Solution Approach 1:
The patent extracts diagnostic information from easily obtainable blood samples rather than requiring invasive tissue sampling. This extraction of molecular markers from liquid biopsy enables repeated monitoring with minimal patient burden, dramatically improving compliance while maintaining high detection accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for non-invasive, sensitive, and specific detection of rare cells, such as CTCs, reducing over-diagnosis and enabling early intervention in metastatic cancer.
Implementation Method 1
The treatment may be applied using ultrasonics, electromagnetics, thermal energy, chemicals, or combinations thereof
Implementation Method 2
The treatment may be applied using ultrasonics, electromagnetics, thermal energy, chemicals, or combinations thereof
Implementation Method 3
The concentration of nucleated cells may be enriched using centrifugation, size separation, or magnetic separation
Implementation Method 4
The concentration of nucleated cells may be enriched using centrifugation, size separation, or magnetic separation
Implementation Method 5
detecting one or more of the predetermined set of biomarkers may comprise using reverse transcription into cDNA
Implementation Method 6
using quantitative Polymerase Chain Reaction (qPCR) with a thermocycler
Implementation Method 7
using TaqMan advanced probes and primers
Data Source
AI summary
A method and apparatus for detecting rare cells in a blood sample. A test sample is obtained by enriching a concentration of nucleated cells in the blood sample. A treated sample is obtained by non-destructively treating the test sample to cause biomarkers to be released from the nucleated cells in the test sample. The measurement of one or more of a predetermined set of biomarkers indicative of rare cells in the treated sample is measured. The measurements from the treated sample are compared to baseline measurements obtained from an untreated sample to predict the presence of the rare cells in the blood sample.